PowerPoint Presentation
Scene 1 (0s)
Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Bortezomib in Combination with Lenalidomide and Dexamethasone (VRd) Joshua Richter 1 , Dominick Latremouille-Viau 2 , Eleanor Saunders 3 , Peggy L. Lin 4 , Christina Tekle 4.
Scene 2 (58s)
Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Bortezomib in Combination with Lenalidomide and Dexamethasone (VRd) Joshua Richter 1 , Dominick Latremouille-Viau 2 , Eleanor Saunders 3 , Peggy L. Lin 4 , Christina Tekle 4.
Scene 3 (1m 44s)
Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Bortezomib in Combination with Lenalidomide and Dexamethasone (VRd) Joshua Richter 1 , Dominick Latremouille-Viau 2 , Eleanor Saunders 3 , Peggy L. Lin 4 , Christina Tekle 4.
Scene 4 (2m 33s)
Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Bortezomib in Combination with Lenalidomide and Dexamethasone (VRd) Joshua Richter 1 , Dominick Latremouille-Viau 2 , Eleanor Saunders 3 , Peggy L. Lin 4 , Christina Tekle 4.
Scene 5 (3m 7s)
Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Bortezomib in Combination with Lenalidomide and Dexamethasone (VRd) Joshua Richter 1 , Dominick Latremouille-Viau 2 , Eleanor Saunders 3 , Peggy L. Lin 4 , Christina Tekle 4.
Scene 6 (3m 38s)
Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Bortezomib in Combination with Lenalidomide and Dexamethasone (VRd) Joshua Richter 1 , Dominick Latremouille-Viau 2 , Eleanor Saunders 3 , Peggy L. Lin 4 , Christina Tekle 4.
Scene 7 (4m 32s)
Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Bortezomib in Combination with Lenalidomide and Dexamethasone (VRd) Joshua Richter 1 , Dominick Latremouille-Viau 2 , Eleanor Saunders 3 , Peggy L. Lin 4 , Christina Tekle 4.
Scene 8 (5m 7s)
Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Bortezomib in Combination with Lenalidomide and Dexamethasone (VRd) Joshua Richter 1 , Dominick Latremouille-Viau 2 , Eleanor Saunders 3 , Peggy L. Lin 4 , Christina Tekle 4.
Scene 9 (5m 43s)
Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Bortezomib in Combination with Lenalidomide and Dexamethasone (VRd) Joshua Richter 1 , Dominick Latremouille-Viau 2 , Eleanor Saunders 3 , Peggy L. Lin 4 , Christina Tekle 4.
Scene 10 (6m 52s)
Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Bortezomib in Combination with Lenalidomide and Dexamethasone (VRd) Joshua Richter 1 , Dominick Latremouille-Viau 2 , Eleanor Saunders 3 , Peggy L. Lin 4 , Christina Tekle 4.
Scene 11 (7m 32s)
Real-World Treatment Characteristics and Clinical Outcomes in Medicare Beneficiaries with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Bortezomib in Combination with Lenalidomide and Dexamethasone (VRd) Joshua Richter 1 , Dominick Latremouille-Viau 2 , Eleanor Saunders 3 , Peggy L. Lin 4 , Christina Tekle 4.